Safety and toxicity of radioembolization plus Sorafenib in advanced hepatocellular carcinoma: analysis of the European multicentre trial SORAMIC. (Q53525194)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Safety and toxicity of radioembolization plus Sorafenib in advanced hepatocellular carcinoma: analysis of the European multicentre trial SORAMIC.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

15 May 2018

http://europepmc.org/abstract/MED/24930619

Safety and toxicity of radioembolization plus Sorafenib in advanced hepatocellular carcinoma: analysis of the European multicentre trial SORAMIC. (English)

1 reference

Europe PubMed Central

15 May 2018

http://europepmc.org/abstract/MED/24930619

multicenter clinical trial

1 reference

based on heuristic

inferred from title

hepatocellular carcinoma

1 reference

based on heuristic

inferred from title

object named as

Bruno Sangro

6

0 references

Peter Malfertheiner

11

object named as

Peter Malfertheiner

1 reference

Europe PubMed Central

15 May 2018

10

object named as

Jerzy Walecki

1 reference

Europe PubMed Central

15 May 2018

http://europepmc.org/abstract/MED/24930619

author name string

Jens Ricke

1

1 reference

Europe PubMed Central

15 May 2018

http://europepmc.org/abstract/MED/24930619

Karsten Bulla

2

1 reference

Europe PubMed Central

15 May 2018

http://europepmc.org/abstract/MED/24930619

Frank Kolligs

3

1 reference

Europe PubMed Central

15 May 2018

http://europepmc.org/abstract/MED/24930619

Markus Peck-Radosavljevic

4

1 reference

Europe PubMed Central

15 May 2018

http://europepmc.org/abstract/MED/24930619

Peter Reimer

5

1 reference

Europe PubMed Central

15 May 2018

http://europepmc.org/abstract/MED/24930619

Eckart Schott

7

1 reference

Europe PubMed Central

15 May 2018

http://europepmc.org/abstract/MED/24930619

Kerstin Schütte

8

1 reference

Europe PubMed Central

15 May 2018

http://europepmc.org/abstract/MED/24930619

Chris Verslype

9

1 reference

Europe PubMed Central

15 May 2018

http://europepmc.org/abstract/MED/24930619

SORAMIC study group

12

1 reference

Europe PubMed Central

15 May 2018

http://europepmc.org/abstract/MED/24930619

publication date

8 July 2014

1 reference

Europe PubMed Central

15 May 2018

http://europepmc.org/abstract/MED/24930619

Liver International

1 reference

Europe PubMed Central

15 May 2018

http://europepmc.org/abstract/MED/24930619

35

1 reference

Europe PubMed Central

15 May 2018

http://europepmc.org/abstract/MED/24930619

2

1 reference

Europe PubMed Central

15 May 2018

http://europepmc.org/abstract/MED/24930619

620-626

1 reference

Europe PubMed Central

15 May 2018

http://europepmc.org/abstract/MED/24930619

Sorafenib in advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12622

21 January 2018

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12622

21 January 2018

EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12622

21 January 2018

Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12622

21 January 2018

Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12622

21 January 2018

Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation.

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12622

21 January 2018

Chemoembolization for hepatocellular carcinoma: comprehensive imaging and survival analysis in a 172-patient cohort.

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12622

21 January 2018

Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12622

21 January 2018

Efficacy and safety of transarterial radioembolization versus chemoembolization in patients with hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12622

21 January 2018

Radioembolization for hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12622

21 January 2018

Radioembolization with 90yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 2: special topics.

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12622

21 January 2018

Multicenter phase II study of sequential radioembolization-sorafenib therapy for inoperable hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12622

21 January 2018

Radioembolization with use of yttrium-90 resin microspheres in patients with hepatocellular carcinoma and portal vein thrombosis

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12622

21 January 2018

Liver disease induced by radioembolization of liver tumors: description and possible risk factors

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12622

21 January 2018

Prognostic factors and prevention of radioembolization-induced liver disease

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12622

21 January 2018

Radioembolization for hepatocellular carcinoma with portal vein thrombosis: impact of liver function on systemic treatment options at disease progression.

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12622

21 January 2018

Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12622

21 January 2018

High serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: importance of tumor biomarker in ablative therapies

1 reference

https://api.crossref.org/works/10.1111%2FLIV.12622

21 January 2018

Identifiers

10.1111/LIV.12622

1 reference

Europe PubMed Central

15 May 2018

http://europepmc.org/abstract/MED/24930619

1 reference

Europe PubMed Central

15 May 2018

http://europepmc.org/abstract/MED/24930619

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53525194&oldid=1963151469"